Condition: Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast Neoplasms · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center ( Site 0066) | Gilbert, Arizona, United States | Recruiting |
| Mayo Clinic Cancer Center ( Site 0034) | Phoenix, Arizona, United States | Recruiting |
| University of Arizona Cancer Center ( Site 0035) | Tucson, Arizona, United States | Recruiting |
| Roy and Patricia Disney Family Cancer Center ( Site 0055) | Burbank, California, United States | Recruiting |
| Community Cancer Institute ( Site 0100) | Clovis, California, United States | Recruiting |
| Providence Medical Foundation ( Site 0080) | Fullerton, California, United States | Recruiting |
| MemorialCare Health System - Long Beach Medical Center ( Site 9556) | Long Beach, California, United States | Recruiting |
| El Camino Hospital Cancer Center ( Site 0096) | Mountain View, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian ( Site 0010) | Newport Beach, California, United States | Recruiting |
| Helios Clinical Research ( Site 0061) | Whittier, California, United States | Recruiting |
| Intermountain Health Cancer Center Saint Joseph ( Site 0062) | Denver, Colorado, United States | Recruiting |
| Rocky Mountain Cancer Centers (RMCC) ( Site 8006) | Denver, Colorado, United States | Recruiting |
+ 305 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06966700